Treatment With iFRC and Ibrutinib Maintenance Led to Durable PFS in Patients With CLL
February 29th 2024In younger patients with chronic lymphocytic leukemia (CLL), treatment with ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFRC) led to strong progression-free survival (PFS) and durable remission years after treatment.
Intravenous Nipocalimab Infusions Safe, Effective Against Autoantibody-Mediated Diseases
February 29th 2024After being found effective over longer durations with smaller doses, this study found that nipocalimab infusions resulted in a tolerable safety profile and remained effective even in shorter treatment periods and with larger doses.
Review Highlights Potential for Bispecific Antibodies in DLBCL
February 28th 2024Investigators are optimistic about bispecific antibodies (BsAbs) for patients with diffuse large B-cell lymphoma (DLBCL), especially the possibility of combining different BsAbs with distinct targets for stronger treatment outcomes.
Uncertainty, Coping Strategies Common Among Patients With AML, High-Risk MDS
February 2nd 2024Patients with comorbid acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) expressed a desire to discuss treatment options and maintain normalcy; they were not willing to have conversations involving their prognosis and future.